Literature DB >> 26832931

Opioid substitution therapy: Lowering the treatment thresholds.

Georgios Kourounis1, Brian David Wensley Richards1, Evdokia Kyprianou2, Eva Symeonidou2, Minerva-Melpomeni Malliori3, Lampros Samartzis4.   

Abstract

BACKGROUND: Opioid substitution therapy (OST) has been established as the gold standard in treating opioid use disorders. Nevertheless, there is still a debate regarding the qualitative characteristics that define the optimal OST intervention, namely the treatment threshold. The aim of this review is twofold: first, to provide a summary and definition of "treatment thresholds", and second, to outline these thresholds and describe how they related to low and high threshold treatment characteristics and outcomes.
METHOD: We searched the main databases of Medline, PubMed, PsycInfo, EMBASE, CINAHL and the Cochrane Library. Original published research papers, reviews, and meta-analyses, containing the eligible keywords: "opioid substitution", "OST", "low threshold", "high threshold" were searched alone and in combination, up to June, 2015.
RESULTS: Treatment thresholds were defined as barriers a patient may face prior to and during treatment. The variables of these barriers were classified into treatment accessibility barriers and treatment design barriers. There are increasing numbers of studies implementing low threshold designs with an increasing body of evidence suggesting better treatment outcomes compared to high threshold designs.
CONCLUSION: Clinical characteristics of low threshold treatments that were identified to increase the effectiveness of OST intervention include increasing accessibility so as to avoid waiting lists, using personalized treatment options regarding medication choice and dose titration, flexible treatment duration, a treatment design that focuses on maintenance and harm reduction with emphasis on the retention of low adherence patients.
Copyright © 2016. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Addiction; Buprenorphine; Cyprus; Drugs; Harm reduction; Heroin; Methadone; OST; Opioid; Policy; Substitution; Threshold

Mesh:

Substances:

Year:  2015        PMID: 26832931     DOI: 10.1016/j.drugalcdep.2015.12.021

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  49 in total

1.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

2.  Telehealth for Substance-Using Populations in the Age of Coronavirus Disease 2019: Recommendations to Enhance Adoption.

Authors:  Lewei Allison Lin; Anne C Fernandez; Erin E Bonar
Journal:  JAMA Psychiatry       Date:  2020-12-01       Impact factor: 21.596

3.  Applying principles of injury and infectious disease control to the opioid mortality epidemic in North America: critical intervention gaps.

Authors:  Benedikt Fischer; Michelle Pang; Mark Tyndall
Journal:  J Public Health (Oxf)       Date:  2020-11-23       Impact factor: 2.341

4.  Responding to the opioid and overdose crisis with innovative services: The recovery community center office-based opioid treatment (RCC-OBOT) model.

Authors:  Robert D Ashford; Austin M Brown; Jessica McDaniel; Jenna Neasbitt; Chad Sobora; Robert Riley; Lesley Weinstein; Aaron Laxton; Justin Kunzelman; Kyle Kampman; Brenda Curtis
Journal:  Addict Behav       Date:  2019-06-21       Impact factor: 3.913

5.  A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.

Authors:  Ned J Presnall; D A Patterson Silver Wolf; Derek S Brown; Sara Beeler-Stinn; Richard A Grucza
Journal:  J Subst Abuse Treat       Date:  2019-06-15

6.  Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.

Authors:  Noa Krawczyk; Ramin Mojtabai; Elizabeth A Stuart; Michael Fingerhood; Deborah Agus; B Casey Lyons; Jonathan P Weiner; Brendan Saloner
Journal:  Addiction       Date:  2020-02-24       Impact factor: 6.526

7.  Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.

Authors:  C Truong; N Krawczyk; M Dejman; S Marshall-Shah; K Tormohlen; D Agus; J Bass
Journal:  Addict Behav       Date:  2019-01-17       Impact factor: 3.913

Review 8.  Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs.

Authors:  Surita Parashar; Alexandra B Collins; Julio S G Montaner; Robert S Hogg; Michael-John Milloy
Journal:  Curr Opin HIV AIDS       Date:  2016-09       Impact factor: 4.283

9.  Global patterns of opioid use and dependence: harms to populations, interventions, and future action.

Authors:  Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney
Journal:  Lancet       Date:  2019-10-23       Impact factor: 79.321

10.  Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.

Authors:  C J Banta-Green; J R Williams; J M Sears; A S Floyd; J I Tsui; T J Hoeft
Journal:  Drug Alcohol Depend       Date:  2019-12-11       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.